Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VRTX
stocks logo

VRTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.19B
+9.46%
5.160
+29.64%
3.14B
+13.42%
4.889
+20.41%
3.20B
+8.01%
5.000
+10.62%
Estimates Revision
The market is revising Downward the revenue expectations for Vertex Pharmaceuticals Incorporated (VRTX) for FY2025, with the revenue forecasts being adjusted by -0.06% over the past three months. During the same period, the stock price has changed by 11.80%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.06%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.1%
In Past 3 Month
Stock Price
Go Up
up Image
+11.80%
In Past 3 Month
Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 482.53 USD with a low forecast of 401.00 USD and a high forecast of 575.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 482.53 USD with a low forecast of 401.00 USD and a high forecast of 575.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
8 Hold
0 Sell
Moderate Buy
Current: 435.900
sliders
Low
401.00
Averages
482.53
High
575.00
Current: 435.900
sliders
Low
401.00
Averages
482.53
High
575.00
Scotiabank
NULL -> Outperform
initiated
$495
2025-11-12
Reason
Scotiabank
Price Target
$495
2025-11-12
initiated
NULL -> Outperform
Reason
Scotiabank initiated coverage of Vertex Pharmaceuticals with an Outperform rating and $495 price target.
UBS
Buy
downgrade
$553 -> $546
2025-11-07
Reason
UBS
Price Target
$553 -> $546
2025-11-07
downgrade
Buy
Reason
UBS lowered the firm's price target on Vertex Pharmaceuticals to $546 from $553 and keeps a Buy rating on the shares.
Stifel
Hold
downgrade
$455 -> $445
2025-11-04
Reason
Stifel
Price Target
$455 -> $445
2025-11-04
downgrade
Hold
Reason
Stifel lowered the firm's price target on Vertex Pharmaceuticals to $445 from $455 and keeps a Hold rating on the shares. The commercial business appears to have a more narrow variance on a quarter-to-quarter basis, making Vertex "less of a beat-and-raise story and more one that may be dependent on pipeline for significant upside," the analyst tells investors in a post-earnings note.
RBC Capital
Sector Perform
downgrade
$423 -> $415
2025-11-04
Reason
RBC Capital
Price Target
$423 -> $415
2025-11-04
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on Vertex Pharmaceuticals to $415 from $423 and keeps a Sector Perform rating on the shares. Compared to Q2, the company registered a more uneventful quarter, the analyst tells investors in a research note. Vertex's cystic fibrosis, CF, franchise remains healthy, though slow launches elsewhere and increased spend underscore intrinsic limitations to operating leverage growth as the company diversifies, the analyst tells investors in a research note.
Barclays
Gena Wang
Equal Weight
maintain
$408 -> $414
2025-11-04
Reason
Barclays
Gena Wang
Price Target
$408 -> $414
2025-11-04
maintain
Equal Weight
Reason
Barclays analyst Gena Wang raised the firm's price target on Vertex Pharmaceuticals to $414 from $408 and keeps an Equal Weight rating on the shares. The company reported a slight beat in Q3 with a slight raise to the lower end of its revenue guidance, the analyst tells investors in a research note.
BofA
Buy
downgrade
$565 -> $563
2025-10-21
Reason
BofA
Price Target
$565 -> $563
2025-10-21
downgrade
Buy
Reason
BofA lowered the firm's price target on Vertex Pharmaceuticals to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in Q3, remains "bullish" on the strong commercial performance of the CF franchise and multiple shots on goal across the portfolio, the analyst tells investors in a preview.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vertex Pharmaceuticals Inc (VRTX.O) is 21.73, compared to its 5-year average forward P/E of 187.38. For a more detailed relative valuation and DCF analysis to assess Vertex Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
187.38
Current PE
21.73
Overvalued PE
782.80
Undervalued PE
-408.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
22.50
Current EV/EBITDA
16.27
Overvalued EV/EBITDA
46.84
Undervalued EV/EBITDA
-1.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.03
Current PS
437.15
Overvalued PS
55.54
Undervalued PS
-29.48
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 31294.44% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 149.17% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 31294.44% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

VRTX News & Events

Events Timeline

(ET)
2025-11-09
12:11:13
Vertex Pharmaceuticals reveals new findings from RUBY-3 study on povetacicept
select
2025-11-06 (ET)
2025-11-06
14:02:12
FDA Grants Second Round of National Priority Vouchers
select
link
2025-11-03 (ET)
2025-11-03
16:04:42
Vertex Pharmaceuticals announces Q3 adjusted EPS of $4.80, surpassing consensus estimate of $4.58.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-13NASDAQ.COM
ETF Inflow Alert: IWF, KO, VRTX, MCK

  • IWF Price Performance: IWF's 52-week price range is between $308.67 and $493, with the last trade recorded at $475.44, which is compared to its 200-day moving average for technical analysis.

  • ETFs Trading Mechanism: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand, impacting the underlying holdings.

  • Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), which can affect the individual components within the ETFs.

  • Author's Views Disclaimer: The opinions expressed in the article are solely those of the author and do not necessarily represent the views of Nasdaq, Inc.

[object Object]
Preview
4.0
11-12TipRanks
Top Analysts Recommend Buying These 3 Stocks Immediately – November 11, 2025

  • NVIDIA Stock: Analyst Vijay Rakesh from Mizuho Securities maintains a Buy rating on NVIDIA, raising the price target from $210 to $220, indicating over 10% upside potential.

  • Walmart Stock: Analyst Rupesh Parikh from Oppenheimer reaffirms a Buy rating for Walmart, with a price target of $115, suggesting more than 12% upside from current levels.

  • Vertex Pharmaceuticals Stock: Analyst Andrew Fein from H.C. Wainwright reiterates a Buy rating for Vertex Pharmaceuticals, setting a price target of $478, which reflects over 13% upside potential.

  • Investment Tool: For a comprehensive list of recently rated stocks, TipRanks offers a Daily Stock Ratings & Price Targets tool for further research.

[object Object]
Preview
9.0
11-11SeekingAlpha
Vertex Emphasizes Increasing Medicaid Access for Non-Opioid Pain Reliever Journavx

  • Medicaid Coverage Approval: Vertex Pharmaceuticals has received Medicaid coverage approval for its non-opioid pain drug Journavx (suzetrigine) in 18 states, with plans to expand to all 50 states.

  • Drug Pricing and Revenue: Journavx, priced at $15.50 per pill, generated $32.9 million in revenue over nine months, despite its high cost affecting uptake.

  • Prescription Demand: As of mid-October, over 300,000 prescriptions for Journavx have been filled, indicating a growing demand for the medication.

  • Future Growth Prospects: Vertex Pharmaceuticals anticipates 8-9% revenue growth by 2025, driven by its renal pipeline and the launch of new products like Journavx.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vertex Pharmaceuticals Inc (VRTX) stock price today?

The current price of VRTX is 435.9 USD — it has increased 0.43 % in the last trading day.

arrow icon

What is Vertex Pharmaceuticals Inc (VRTX)'s business?

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

arrow icon

What is the price predicton of VRTX Stock?

Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 482.53 USD with a low forecast of 401.00 USD and a high forecast of 575.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vertex Pharmaceuticals Inc (VRTX)'s revenue for the last quarter?

Vertex Pharmaceuticals Inc revenue for the last quarter amounts to 3.08B USD, increased 10.99 % YoY.

arrow icon

What is Vertex Pharmaceuticals Inc (VRTX)'s earnings per share (EPS) for the last quarter?

Vertex Pharmaceuticals Inc. EPS for the last quarter amounts to 4.20 USD, increased 4.74 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vertex Pharmaceuticals Inc (VRTX)'s fundamentals?

The market is revising Downward the revenue expectations for Vertex Pharmaceuticals Incorporated (VRTX) for FY2025, with the revenue forecasts being adjusted by -0.06% over the past three months. During the same period, the stock price has changed by 11.80%.
arrow icon

How many employees does Vertex Pharmaceuticals Inc (VRTX). have?

Vertex Pharmaceuticals Inc (VRTX) has 6100 emplpoyees as of November 18 2025.

arrow icon

What is Vertex Pharmaceuticals Inc (VRTX) market cap?

Today VRTX has the market capitalization of 110.12B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free